Aurinia Pharmaceuticals Files 8-K for Shareholder Votes & Financials
Ticker: AUPH · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1600620
| Field | Detail |
|---|---|
| Company | Aurinia Pharmaceuticals Inc. (AUPH) |
| Form Type | 8-K |
| Filed Date | Jun 14, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, corporate-governance, financials
Related Tickers: AUPH
TL;DR
AURIN just filed an 8-K for shareholder votes and financials - check for details.
AI Summary
Aurinia Pharmaceuticals Inc. filed an 8-K on June 14, 2024, to report on matters submitted to a vote of security holders and financial statements. The filing does not contain specific details on the votes or financial results within the provided text, but indicates these are being formally reported.
Why It Matters
This filing is a routine update for investors, signaling that important corporate actions, such as shareholder votes and financial reporting, are being officially documented with the SEC.
Risk Assessment
Risk Level: low — This is a standard SEC filing for reporting corporate events and does not inherently introduce new risks.
Key Players & Entities
- Aurinia Pharmaceuticals Inc. (company) — Registrant
- June 14, 2024 (date) — Date of Report
FAQ
What specific matters were submitted to a vote of security holders?
The provided text of the 8-K filing indicates that matters were submitted to a vote of security holders, but does not specify what those matters were.
What financial statements are included in this filing?
The filing states that 'Financial Statements and Exhibits' are included, but the specific financial statements are not detailed in the provided excerpt.
What is the company's principal executive office address?
The company's principal executive office is located at #140, 14315 – 118 Avenue, Edmonton, Alberta T5L 4S6.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What is the SEC Act under which this report is filed?
This report is filed under the 1934 Act.
Filing Stats: 817 words · 3 min read · ~3 pages · Grade level 9.6 · Accepted 2024-06-14 17:25:28
Filing Documents
- auph-20240614.htm (8-K) — 52KB
- 0001600620-24-000087.txt ( ) — 174KB
- auph-20240614.xsd (EX-101.SCH) — 2KB
- auph-20240614_lab.xml (EX-101.LAB) — 21KB
- auph-20240614_pre.xml (EX-101.PRE) — 12KB
- auph-20240614_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. (a) The Company held its annual general meeting of shareholders (the "2024 Meeting") virtually on June 14, 2024. (b) The following proposals were voted upon at the 2024 Meeting and the final voting results with respect to each such proposal are set forth below: Proposal 1: At the 2024 Meeting, shareholders voted on the election of Dr. Daniel Billen, Mr. Peter Greenleaf, Dr. David R.W. Jayne, Mr. R. Hector MacKay-Dunn, Ms. Jill Leversage, Dr. Brinda Balakrishnan, Dr. Karen Smith, Mr. Jeffrey A. Bailey and Dr. Robert T. Foster to serve as members of the Company's board of directors until the annual general meeting of shareholders to be held in 2025. Nominee For Withheld Broker Non-Votes Dr. Daniel Billen 33,343,245 43,247,441 19,865,665 Mr. Peter Greenleaf 36,942,214 39,681,657 19,832,480 Dr. David R.W. Jayne 47,961,382 28,672,488 19,822,481 Mr. R. Hector MacKay-Dunn 35,001,819 41,588,866 19,865,666 Ms. Jill Leversage 48,882,668 27,741,202 19,832,481 Dr. Brinda Balakrishnan 36,406,544 40,184,139 19,865,668 Dr. Karen Smith 38,979,544 37,644,485 19,832,322 Mr. Jeffrey A. Bailey 38,651,711 37,972,319 19,832,321 Dr. Robert T. Foster 39,405,046 37,218,984 19,832,321 Shareholders re-elected five of nine incumbent directors to the Board of Directors (the Board). The four directors, while elected under applicable corporate law, who received less than majority support are Peter Greenleaf, Director, President and CEO; Daniel G. Billen, Ph.D., Director, Chair of the Board, Chair of the Compensation Committee, and Member of the Audit Committee; R. Hector MacKay-Dunn, J.D., K.C., Director, Chair of the Governance & Nomination Committee and Member of the Compensation Committee; and Brinda Balakrishnan, M.D., Ph.D., Director, Member of the Compensation Committee. As required by the Company's Majority Voting Policy, these directors have submitted their conditional resignations as directors of the Com
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 14, 2024 AURINIA PHARMACEUTICALS INC. By: /s/ Stephen P. Robertson Name: Stephen P. Robertson Title: Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer